Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

IgA nephropathy (IgAN) is characterized by the deposition of IgA1-containing immune complexes in the glomerular mesangium. The pathogenesis follows a 4-hit cascade: ...

Immunoglobulin A (IgA) nephropathy is a condition that causes a certain type of protein to build up in your kidneys. It progresses differently in everyone. Your kidneys might still work well years ...

IgA Nephropathy Foundation: “IgA Nephropathy – What You Need to Know.” Cleveland Clinic: “IgA Nephropathy.” National Institute of Diabetes and Digestive and Kidney Diseases ...

Immunoglobulin A nephropathy (also known as IgA nephropathy or Berger's disease) is a condition that causes IgA antibodies to accumulate in the kidneys—leading to damage that affects their blood ...

An increase in the proportion of serum IgA molecules that are poorly O-galactosylated has been one of the most consistent findings in studies of IgAN over the past decade. 1,2 Perhaps more ...

Fibroblast activating protein inhibitor (FAPI) PET/CT imaging may be a non-invasive modality to monitor IgA nephropathy (IgAN) progression, preliminary study results suggest.

Andrew S. Bomback, MD, MPH, comments on the impact of disparities in diagnosing and treating IgA nephropathy by nephrologists. Early detection and treatment of IgA nephropathy are critical for ...